Theratechnologies Presents New Tesamorelin Data 23-02-2023, 05:33

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

C.K. McWhorter Endows America's Cup Regatta with Prestigious McWhorter Family Trust Warrant of Excellence 10-04-2024, 03:49